| http://purl.uniprot.org/citations/38169186 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/38169186 | http://www.w3.org/2000/01/rdf-schema#comment | "Liver cancer is the fourth most lethal cancer, but the treatment options for liver cancer are usually limited. Metabolic reprogramming is a hallmark of malignancy, ensuring activated cell glycolysis and increased macromolecular precursors required for the proliferation and migration of exuberant cancer cells. MicroRNAs (miRNAs) have been reported to participate in cancer metabolic shifts mainly by directly silencing the expression of specific genes. Here, we identified miR-148a-3p as a negative regulator for glycometabolism and cell proliferation in liver cancer. miR-148a-3p directly targets the 3'UTR of transmembrane protein 54 (TMEM54), leading to the significant inhibition of lactate production, glucose consumption, intracellular ATP level and extracellular acidification rate (ECAR), as well as the repression of the proliferation and colony formation ability of liver cancer cells. miR-148a-3p expression is often down-regulated in liver cancer tissues. In addition, there was a negative correlation between the expression levels of miR-148a-3p and TMEM54 in liver cancer tissues. Moreover, the low miR-148a-3p expression levels or high TMEM54 expression levels were associated with poorer prognosis in hepatocellular carcinoma (HCC) patients. Together, these findings support that the miR-148a-3p/TMEM54 regulatory pathway regulates the glycometabolism and cell proliferation in liver cancer, which is a possible target for the diagnosis and treatment of liver cancer."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.bbrc.2023.149424"xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/author | "Ding J."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/author | "Wen Y."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/author | "Yuan X."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/author | "Zhao Y."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/author | "Shi Q."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/date | "2024"xsd:gYear |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/name | "Biochem Biophys Res Commun"xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/pages | "149424"xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/title | "MicroRNA-148a-3p suppresses the glycolysis and Cell proliferation by targeting transmembrane protein 54 in liver cancer."xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://purl.uniprot.org/core/volume | "695"xsd:string |
| http://purl.uniprot.org/citations/38169186 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/38169186 |
| http://purl.uniprot.org/citations/38169186 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/38169186 |
| http://purl.uniprot.org/uniprot/#_Q969K7-mappedCitation-38169186 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/38169186 |
| http://purl.uniprot.org/uniprot/Q969K7 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/38169186 |